{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:47:33Z","timestamp":1778201253784,"version":"3.51.4"},"reference-count":17,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T00:00:00Z","timestamp":1757462400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Background: Hormone receptor-positive (HR+), HER2\u2212 negative metastatic breast cancer (MBC) is the most common subtype of advanced breast cancer. Resistance to endocrine therapy often develops, particularly after CDK4\/6 inhibitors. Everolimus, an mTOR inhibitor, may restore hormone sensitivity, but real-world data after CDK4\/6 and chemotherapy are limited. Methods: This retrospective, single-center study included 70 patients with HR+\/HER2\u2212 MBC who progressed on CDK4\/6 inhibitors and at least one line of chemotherapy. All received daily oral everolimus (10 mg) plus exemestane (25 mg). Tumor response was assessed via RECIST v1.1, and survival outcomes were estimated using the Kaplan\u2013Meier method. Results: Median progression-free survival was 6.6 months and overall survival was 22.6 months. The disease control rate was 88.6%, with 57.1% showing partial response. Fatigue (20%), skin toxicity (8.6%), and stomatitis (5.7%) were the most common adverse events. No grade 3\u20134 toxicities or discontinuations occurred. No clinical or pathological variables significantly influenced survival. Conclusions: Everolimus plus exemestane provided meaningful clinical benefit and manageable toxicity in heavily pretreated HR+\/HER2\u2212 MBC patients. This regimen remains a valid later-line option, particularly in settings with limited access to newer targeted therapies or genomic testing.<\/jats:p>","DOI":"10.3390\/curroncol32090503","type":"journal-article","created":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T08:43:54Z","timestamp":1757493834000},"page":"503","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Single-Center Real World Study of Everolimus and Exemestane in HR+\/HER2\u2212 Metastatic Breast Cancer Following CDK4\/6 Inhibitor Therapy"],"prefix":"10.3390","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0634-7350","authenticated-orcid":false,"given":"Yunus Emre","family":"Alt\u0131nta\u015f","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Kartal Dr. L\u00fctfi K\u0131rdar City Hospital, Istanbul 34865, T\u00fcrkiye"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5983-3291","authenticated-orcid":false,"given":"O\u011fuzcan","family":"K\u0131n\u0131ko\u011flu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Kartal Dr. L\u00fctfi K\u0131rdar City Hospital, Istanbul 34865, T\u00fcrkiye"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4398-5148","authenticated-orcid":false,"given":"Deniz","family":"I\u015f\u0131k","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Kartal Dr. L\u00fctfi K\u0131rdar City Hospital, Istanbul 34865, T\u00fcrkiye"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aziz","family":"Batu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, \u00dcmraniye Training and Research Hospital, Istanbul 34760, T\u00fcrkiye"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1782-7808","authenticated-orcid":false,"given":"Ayberk","family":"Bayramgil","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, \u00dcmraniye Training and Research Hospital, Istanbul 34760, T\u00fcrkiye"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B\u00fc\u015fra","family":"Ni\u011fdelio\u011flu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, \u00dcmraniye Training and Research Hospital, Istanbul 34760, T\u00fcrkiye"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"U\u011fur","family":"\u00d6zkerim","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Kartal Dr. L\u00fctfi K\u0131rdar City Hospital, Istanbul 34865, T\u00fcrkiye"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4721-0585","authenticated-orcid":false,"given":"S\u0131la","family":"\u00d6ks\u00fcz","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Kartal Dr. L\u00fctfi K\u0131rdar City Hospital, Istanbul 34865, T\u00fcrkiye"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1604-8466","authenticated-orcid":false,"given":"Heves","family":"S\u00fcrmeli","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Kartal Dr. L\u00fctfi K\u0131rdar City Hospital, Istanbul 34865, T\u00fcrkiye"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1140-8779","authenticated-orcid":false,"given":"Nedim","family":"Turan","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Kartal Dr. L\u00fctfi K\u0131rdar City Hospital, Istanbul 34865, T\u00fcrkiye"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5757-4705","authenticated-orcid":false,"given":"Hatice","family":"Odaba\u015f","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Kartal Dr. L\u00fctfi K\u0131rdar City Hospital, Istanbul 34865, T\u00fcrkiye"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,9,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1158\/1078-0432.CCR-09-1823","article-title":"New strategies in estrogen receptor\u2013positive breast cancer","volume":"16","author":"Johnston","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"ref_2","first-page":"4845","article-title":"American Society of Clinical Oncology Clinical Practice Guideline: Endocrine therapy for hormone receptor\u2013positive metastatic breast cancer","volume":"29","author":"Burstein","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_3","first-page":"2596","article-title":"Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer","volume":"19","author":"Bonneterre","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1200\/JCO.2007.13.5822","article-title":"Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: Results from EFECT","volume":"26","author":"Chia","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1056\/NEJMra023246","article-title":"Aromatase inhibitors in breast cancer","volume":"348","author":"Smith","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1109653","article-title":"Everolimus in postmenopausal hormone-receptor\u2013positive advanced breast cancer","volume":"366","author":"Baselga","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_7","first-page":"648","article-title":"Final progression-free survival analysis of BOLERO-2","volume":"15","author":"Piccart","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/nature04871","article-title":"Hypoxia signaling in cancer and approaches to enforce tumour regression","volume":"441","author":"Dayan","year":"2006","journal-title":"Nature"},{"key":"ref_9","unstructured":"T.C. Sosyal G\u00fcvenlik Kurumu (2024). Sa\u011fl\u0131k Uygulama Tebli\u011fi (SUT), T.C. Sosyal G\u00fcvenlik Kurumu."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s40265-013-0034-2","article-title":"Everolimus in combination with exemestane: A review of its use in the treatment of patients with postmenopausal hormone receptor-positive, HER2-negative advanced breast cancer","volume":"73","author":"Dhillon","year":"2013","journal-title":"Drugs"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1001\/jamaoncol.2018.2262","article-title":"Everolimus Plus Exemestane vs Everolimus or Capecitabine Monotherapy for Estrogen Receptor\u2013Positive, HER2-Negative Advanced Breast Cancer: The BOLERO-6 Randomized Clinical Trial","volume":"4","author":"Jerusalem","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3246","DOI":"10.1200\/JCO.22.00338","article-title":"Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for ER-positive, HER2-negative advanced breast cancer: Results from the randomized phase III EMERALD trial","volume":"40","author":"Bidard","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1056\/NEJMoa1813904","article-title":"Alpelisib for PIK3CA-mutated, hormone receptor\u2013positive advanced breast cancer","volume":"380","author":"Ciruelos","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e629","DOI":"10.1016\/S1470-2045(24)00673-9","article-title":"Alpelisib plus fulvestrant in PIK3CA mutated, hormone receptor positive advanced breast cancer after CDK4\/6 inhibitor failure (BYLieve): Phase II cohort A","volume":"25","author":"Rugo","year":"2024","journal-title":"Lancet Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"4177","DOI":"10.1158\/1078-0432.CCR-20-2114","article-title":"TRINITI-1: A phase I\/II study of ribociclib, everolimus, and exemestane in patients with HR-positive, HER2-negative advanced breast cancer after progression on a CDK4\/6 inhibitor","volume":"27","author":"Bardia","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1038\/s41467-024-45835-6","article-title":"Exemestane plus everolimus and palbociclib in metastatic breast cancer: Clinical response and genomic\/transcriptomic determinants of resistance in a phase I\/II trial","volume":"15","author":"Jain","year":"2024","journal-title":"Nat. Commun."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/32\/9\/503\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:43:01Z","timestamp":1760035381000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/32\/9\/503"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,10]]},"references-count":17,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["curroncol32090503"],"URL":"https:\/\/doi.org\/10.3390\/curroncol32090503","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,10]]}}}